A DOUBLE-BLIND RANDOMIZED CROSSOVER STUDY TO COMPARE THE ANTIEMETIC EFFICACY OF 250 MG WITH 500 MG METHYLPREDNISOLONE SUCCINATE (SOLU-MEDROL) AS A SINGLE INTRAVENOUS DOSE IN PATIENTS TREATED WITH NONCISPLATIN CHEMOTHERAPY

Citation
Rc. Pieters et al., A DOUBLE-BLIND RANDOMIZED CROSSOVER STUDY TO COMPARE THE ANTIEMETIC EFFICACY OF 250 MG WITH 500 MG METHYLPREDNISOLONE SUCCINATE (SOLU-MEDROL) AS A SINGLE INTRAVENOUS DOSE IN PATIENTS TREATED WITH NONCISPLATIN CHEMOTHERAPY, Oncology, 50(4), 1993, pp. 316-322
Citations number
26
Categorie Soggetti
Oncology
Journal title
ISSN journal
00302414
Volume
50
Issue
4
Year of publication
1993
Pages
316 - 322
Database
ISI
SICI code
0030-2414(1993)50:4<316:ADRCST>2.0.ZU;2-0
Abstract
A double-blind randomized crossover study was performed in 56 chemothe rapy-naive patients, all receiving non-cisplatin-based chemotherapy, t o compare the antiemetic effects of 2 doses of a single administration of methylprednisolone succinate (Solu-Medrol): 250 versus 500 mg. Amo ng the 39 patients who satisfactorily completed both parts of the stud y, complete and major protection from emesis (0 and 1 emetic episode o r only retching) was observed in 79% during the first course and in 69 % during the second course. Treatment failure (greater-than-or-equal-t o 6 episodes of vomiting) was observed in 18 % during the first course and 21% during the second course. There was no significant difference between the two dose levels neither in terms of antiemetic protection nor in terms of the occurrence of side effects nor in patient prefere nce. Most important side effects were facial flushing (45%), headache (22%) and facial edema (18%). It is concluded that. although a compari son with lower dosages cannot be made, within the dose range studied n o clear dose-reponse relationship could be found.